Advantages of pegfilgrastim over filgrastim in managing chemotherapy-induced febrile neutropenia
Subgroup analysis of OAK trial data supports use of atezolizumab in patients with NSCLC
The crossroads of targeted therapy and immunotherapy in lung cancer
PARP inhibitors: game-changers for ovarian cancer patients?
Mansoor Raza Mirza
The role of nicotine in cancer and its impact on therapy